Company Overview
- CentricsBio Inc. is a biotech venture company established
in 2017 with the goal of developing new global drugs. Having held
the patent for a cancer immunotherapy drug, we develop more
innovative drugs using that. - Our company currently has its head office/research center in Munjeong-dong, Songpa-gu, and is conducting joint research by forming networks with leading domestic and overseas research institutes to expand various pipelines and indications. Based on this potential, CentricsBio Inc. has already succeeded in attracting a large number of investments, and all employees are striving to launch a new blockbuster drug to become a worldwide company.
Company Milestones
2025
- 05Published SCI paper on Alzheimer's efficacy in Biomedicine
- 02Presented at the Hankyung Bio Insight Forum
- 02Dr. Seungseo Hong appointed as CSO/COO
- 01Surpassed 54 patent applications and 11 registrations
2024
- 07Patent registered for CB303
- 05Patent registered for CB301
- 01Patent application filed for CB601
- 01Patent application filed for CB701
2023
- 12Published SCI paper in Immunobiology
- 11Selected for the national dementia research program (KDRC)
- 11Patent registered for CB303
- 06Signed MoU with BioPlus
- 03Patent application filed for CB201
2022
- 11Patent registered for monoclonal antibody
- 10Patent registered for antigen source technology
2021
- 12Selected for the national new drug development project (KDDF)
- 09Presented research at the European Society for Medical Oncology (ESMO)
- 07Registered original patent for CB301
2020
- 10Filed CB301 patents in six countries
- 09Entered joint research agreement with CHA University & CHA General Hospital
- 01Filed original patent application for CB304
2019
- 11Patent application filed for CB301
- 10Patent application filed for CB303
- 09 Established office in Munjeong-dong, Seoul